



Innovative back microsurgery

Press release

Clinical Biomechanics publishes a study proving the excellent performances of the SpineJack®

This biomechanical study measures the anatomical restoration of vertebrae with the SpineJack® compared to balloon kyphoplasty

Toulouse, September 12th 2013 - VEXIM (FR0011072602 - ALVXM), a medical device company specializing in the minimally-invasive treatment of vertebral fractures, today announces that the results of a comparative biomechanical study carried out by Marburg University's Traumatology department (Germany) were published in the August issue of the CLINICAL BIOMECHANICS international journal.

The aim of this study was to evaluate the anatomic restoration of 36 fractured vertebral bodies with osteoporosis and the maintaining of the gained height after recompression by comparing the SpineJack® and balloon kyphoplasty techniques.

The results obtained demonstrate a significant advantage in favor of the SpineJack® regarding the restoration of vertebral height that is carried out to reestablish the spinal column's balance.

"The vertebral height restoration was over 93% for the groups treated with SpineJack® even after recompression", said Dr. Antonio Krüger, Orthopedic Trauma surgeon in trauma and reconstructive surgery at the Philipp's University (Marburg) and the study's main investigator.

Vincent Gardès, CEO of VEXIM, concludes: *"I would first and foremost like to congratulate Dr. Antonio Krüger's team for the publication of their study in this highly-recognized journal for clinicians and scientists. These results clearly show the advantages of the SpineJack®, and further increase our confidence in the pursuance of our clinical program."*

The abstract of the article entitled "Height restoration and maintenance after treating unstable osteoporotic vertebral compression fractures by cement augmentation is dependent on the cement volume used" is available on line: [http://www.clinbiomech.com/article/S0268-0033\(13\)00142-3/abstract](http://www.clinbiomech.com/article/S0268-0033(13)00142-3/abstract).

Every year, 1.4 million new cases of osteoporotic vertebral fractures are diagnosed in Europe¹ and 700,000 in the United States².

¹ Felsenberg et al.2002

² International Osteoporosis Foundation

About Vexim, the innovative back microsurgery specialist

Based in Balma, near Toulouse (France), Vexim is a medical device company created in February 2006. The Company has specialized in the creation and marketing of mini-invasive solutions for treating traumatic spinal pathologies. Benefitting from the financial support of its longstanding shareholders, Truffle Capital¹ and Banexi Venture, and from OSEO public subsidies, Vexim has designed and developed the SpineJack[®], a unique implant capable of repairing a fractured vertebra and restoring the balance of the spinal column. The Company currently has 48 staff. It has its own sales teams in France, Germany, Italy, Spain, Switzerland and the United Kingdom, as well as distributors notably in Turkey, Argentina, India, Taiwan and in the following countries where the product is currently being registered: Mexico, Brazil, Colombia, Venezuela, Chile, Ecuador and Peru. Vexim has been listed on NYSE Alternext Paris since May 3rd 2012.

For further information, please go to www.vexim.com

SpineJack^{®2}, a revolutionary implant for treating Vertebral Compression Fractures

The revolutionary aspect of the SpineJack[®] lies in its ability to restore a fractured vertebra to its original shape, restore the spinal column's optimal anatomy and thus remove pain and enable the patient to recover their functional capabilities. Thanks to a specialized range of instruments, inserting the implants into the vertebra is carried out by mini-invasive surgery, guided by X-ray, in approximately 30 minutes, enabling the patient to be discharged shortly after surgery. The SpineJack[®] range consists of 3 titanium implants with 3 different diameters, thus covering 95% of vertebral compression fractures and all patient morphologies.

SpineJack[®] technology benefits from the support of international scientific experts in the field of spine surgery and worldwide patent protection through to 2029.

Contacts

VEXIM

Vincent Gardès

CEO

Tel: +33 5 61 48 48 38

investisseur@vexim.com

NewCap.

Financial Communications
and Investor Relations

Dusan Oresansky /

Emmanuel Huynh

Tel: +33 1 44 71 94 92

vexim@newcap.fr

Alize RP

Press Relations

Caroline Carmagnol

caroline@alizerp.com

Tel: +33 6 64 18 99 59

Christian Berg

christian@alizerp.com

Tel: +33 1 70 22 53 86



- **Name:** Vexim
- **ISIN Code:** FR0011072602
- **Ticker:** ALVXM

¹ Founded in 2001 in Paris, Truffle Capital is a leading independent European private equity firm. It is dedicated to investing in and building technology leaders in the IT, life sciences and energy sectors. Truffle Capital manages €550m via FCPRs and FCPIs, the latter offering tax rebates (funds are blocked during 7 to 10 years). For further information, please visit www.truffle.fr and www.fcpi.fr.

² This medical device is a regulated health product that, with regard to these regulations, bears the CE mark. Please refer to the instructions leaflet.